Aberrant expressions of endometrial Id3 and CTLA-4 are associated with unexplained repeated implantation failure and recurrent miscarriage

Aberrant expressions of endometrial Id3 and CTLA-4 are associated with unexplained repeated implantation failure and recurrent miscarriage
复制标题

子宫内膜 Id3 和 CTLA-4 的异常表达与不明原因的反复着床失败和复发性流产相关

DOI:
10.1111/aji.12632
复制
发表时间:
2017-08-01
影响因子:
3.6
通讯作者:
Yang, Jing
Yang, Jing
中科院分区:
医学3区
文献类型:
--
作者:
Ding, Jin-Li;Diao, Liang-Hui;Yang, Jing

文献摘要

被引文献

相似文献

dna结合蛋白3抑制剂(Id3)是肿瘤血管生成和调节性t细胞生成所必需的。然而,Id3在不明原因重复植入失败(RIF)和复发性流产(RM)中的作用仍然知之甚少。采用免疫组织化学方法鉴定取自RIF (n=16)、RM (n=16)和匹配对照(n=8)的子宫内膜中的Id3、CD34、CTLA-4和FOXP3。图像由Vectra((R))自动定量病理成像系统采集和分析。与对照组相比,RIF和RM患者子宫内膜中Id3(+)细胞的百分比明显更高。对照组子宫内膜中Id3(+)和CD34(+)血管数量呈正相关,而RIF和RM则无相关。与对照组相比,RIF和RM女性子宫内膜中CTLA-4(+)细胞的百分比显著增加,而FOXP3(+)细胞的百分比则没有显著增加。我们发现子宫内膜Id3和CTLA-4在RIF和RM患者的着床周子宫内膜中异常表达,提示这些血管生成和免疫耐受标志物参与调节子宫内膜容受性的负面作用。
Inhibitor of DNA-binding protein 3 (Id3) is required for tumor angiogenesis and regulatory T-cell generation. However, the involvement of Id3 in unexplained repeated implantation failure (RIF) and recurrent miscarriage (RM) remains poorly understood. Immunohistochemistry was used to identify Id3, CD34, CTLA-4, and FOXP3 in the endometrium taken from the women with RIF (n=16), RM (n=16) and matched controls (n=8). The images were acquired and analyzed by the Vectra((R)) automated quantitative pathology imaging system. Percentage of Id3(+) cells was significantly higher in the endometrium of women with RIF and RM compared with controls. The numbers of Id3(+) and CD34(+) vessels in the endometrium were positively correlated in control but not in RIF or RM. Percentages of CTLA-4(+) cells, but not FOXP3(+) cells, were significantly increased in the endometrium of RIF and RM women than those in controls. We found aberrant expressions of endometrial Id3 and CTLA-4 in peri-implantation endometrium of women with RIF and RM, suggesting the negative roles of these angiogenesis and immune tolerance markers involving in regulating endometrium receptivity.